Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Crucell, Wyeth In Merger Talks

by Patricia L. Short
January 12, 2009 | A version of this story appeared in Volume 87, Issue 2

Dutch biopharmaceutical producer Crucell says it is "in friendly discussions with Wyeth that may lead to a combination of the two companies." The discussions are at a preliminary stage, with no certainty that they will result in a transaction, Crucell said in a statement sent to the Dutch financial authorities. According to published reports, a deal could be worth more than $1.3 billion. In 2007, Crucell rang up roughly $276 million in sales and license and service fees. It specializes in vaccines, a field that Wyeth also is active in. Crucell also licenses its Per.C6 production cell line technology for vaccine and protein production.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.